secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001129928-26-000026
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncolytics secures FDA alignment on pivotal anal cancer study for pelareorep
----------------------------------------------------------------------------

- FDA agreed on a randomized controlled pivotal trial design for pelareorep in post-first-line metastatic SCAC, targeting accelerated and full approval.
- Prior pelareorep+checkpoint data showed median duration of response 15.5 months vs 9.5 months SOC; 12-month survival 82% vs 45.7%.
- No FDA-approved therapies exist for SCAC after first-line chemo/checkpoint; over 10,000 US patients affected annually.
- Company will finalize protocol using FDA feedback; study enables multiple endpoint assessments for potential simultaneous approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000026/0001129928-26-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000026/oncy-20260427.htm
  HTML page:      https://secwatch.observer/filing/0001129928-26-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer